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a b s t r a c t 
Neurodegenerative diseases are characterized by progressive degeneration of selective neurones in the nervous 25 
system, but the underlying mechanisms involved in neuroprotection and neurodegeneration remain unclear. 26 
Dysfunction of the ubiquitin proteasome system is one of the proposed hypotheses for the cause and progression 27 
of neuronal loss. Wehave performed quantitative two-dimensional fluorescence difference in-gel electrophoresis 28 
combined with peptide mass fingerprinting to reveal proteome changes associated with neurodegeneration 29 
following 26S proteasomal depletion in mouse forebrain neurones . Differentially expressed proteins were 30 
validated by Western blotting, biochemical assays and immunohistochemistry. Of significance was 31 
increased expression of the antioxidant enzyme peroxiredoxin 6 (PRDX6) in astrocytes, associated wi th 32 
oxidative stress. Interestingly, PRDX6 is a bifunctional enzyme with antioxidant peroxidase and phospholipase 33 
A2 (PLA2) activities. The PLA2 activity of PRDX6 was also increased following 26S proteasomal depletion and may 34 
be involved in neuroprotective or neurodegenerative mechanisms. This is the first in vivo report of oxidative 35 
stress caused directly by neuronal proteasome dysfunction in the mammalian brain. The results contribute to 36 
understanding neuronal–glial interactions in disease pathogenesis, provide an in vivo link between prominent 37 
disease hypotheses and importantly, are of relevance to a heterogeneous spectrum of neurodegenerative 38 
diseases. 39 
© 2013 The Authors. Published by Elsevier B.V. All rights reserved. 40 
44 
43 
45 1. Introduction 
46 Neurodegenerative diseases are characterized by the progressive 
47 degeneration of selective neurones of the nervous system. Abnormal 
48 protein aggregation, impaired protein degradation, mitochondrial 
49 dysfunction and oxidative stress are key hypotheses for cause and 
50 progression of major human neurodegenerative diseases, including 
51 Alzheimer's disease (AD) and Parkinson's disease (PD) [1–3]. Attention 
52 has also turned to the contribution of glial cells to neurodegeneration 
53 [4], but the underlying mechanisms involved in neuroprotection and 
54 neurodegeneration in the nervous system remain unclear. 
55 The ubiquitin proteasome system (UPS) is the major intracellular 
56 pathway for regulated degradation of unwanted proteins and central 
57 to normal cellular homeostasis [5]. A sequence of enzymes covalently 
58 attach polyubiquitin chains to unwanted proteins as a signal for 
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degradationbythe 26S proteasome. Studiesinhuman brain and disease 59 
models have implicated dysfunction of the UPS in the pathological 60 
changes that lead to neurodegeneration [6–9]. Ubiquitin-positive 61 
protein inclusions are a common feature of human neurodegenerative 62 
diseases [6]. Also, in PD and dementia with Lewy bodies (DLB) patients, 63 
altered proteasome activity and subunit expression has been reported 64 
[7]. In a significant study, we showed that genetic depletion of 26S 65 
proteasomes in mouse brain neurones caused neurodegeneration and 66 
the formation of protein inclusions resembling human pale bodies, the 67 
precursor of Lewy bodies, providing a compelling link between 68 
UPS-mediated protein degradation and neurodegeneration [10]. 69 
Proteomic studies are of considerable interest to identify 70 
much-needed novel pathogenic mechanisms connected to neurode- 71 
generative disease. There are inherent difficulties with a study of a 72 
mixture of cell-types in the brain, but it is essential to investigate 73 
in vivo models to identify the importance of neuronal–glial cellular 74 
interactions during disease development that are not revealed in 75 
studies of cell lines composed of a single clonal cell-type. We have 76 
employed a quantitative two-dimensional fluorescence difference 77 
in-gel electrophoresis (2D-DIGE) proteomic approach to reveal 78 
proteome changes associated with cortical neurodegeneration 79 
following 26S proteasomal depletion in our unique mouse model. 80 
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81 Protein changes identified in our 2D-DIGE study were validated by 
82 alternative approaches, namely 1D and 2D Western blotting as well 
83 as biochemical and immunohistochemical investigations to further 
84 understand their significance. The results show new information 
85 linking UPS dysfunction to oxidative stress in the brain in vivo and 
86 the importance of understanding neuronal–glial interactions during 
87 disease progression. 
88 2. Materials and methods 
89 2.1. 26S proteasomal depletion mouse model 
90 Neurone-specific 26S proteasome-depleted micewerecreatedusing 
91 Cre/loxP conditional gene targeting as described in detail previously 
92 [10]. For forebrain, including cortex, neurone-specific inactivation of 
93 Psmc1, Cre recombinase was expressed under the control ofthe calcium 
94 calmodulin-dependent protein kinase IIα promoter (Psmc1 f l / f l ; 
95 CaMKIIα-Cre) [10]. CaMKIIα is expressed in post-mitotic neurones 
96 from approximately post-natal week 2 [11,12]. Appropriate litter-
97 mate mice were used as controls. 
98 All procedures were carried out under personal and project licenses 
99 granted by the UK Home Office in accordance with the Animals (Scientific 
100 Procedures) Act 1986 and with ethical approval from the University of 
101 Nottingham Ethical Review Committee. 
102 2.2. 2D fluorescence difference in-gel electrophoresis (2D-DIGE) 
103 Mouse cortex was homogenized in lysis buffer containing 30 mM 
104 Tris–HClpH 8.8,8 MUrea and 4% (w/v) CHAPS, followed bycentrifuga-
105 tion at 20,000 g for 5 min at 4 °C and collection of supernatant. Protein 
106 estimation used the Bio-Rad (Bradford) protein assay kit. CyDye 
107 labeling was performed according to the manufacturer's instructions 
108 (GE Healthcare) and incorporating a dye swap. 15 μg of each sample 
109 was labeled with Cy3 and Cy5, and a pooled sample was labeled with 
110 Cy2 containing equal amounts of all samples as an internal standard. 
111 10 mM lysine was used to stop labeling. First dimension isoelectric 
112 focusing (IEF) used a Bio-Rad Protein IEF Cell and 7 cm 3–10 
113 non-linear pH gradient IPG strips (Bio-Rad). Strips were passively 
114 rehydrated for 1 h, actively rehydrated for 13 h and 40 min at 50 V 
115 followed by IEF (250 V for 20 min linear, 4000 V for 2 h linear, 
116 4000 V for 10,000 V/h rapid). The strips were incubated in 2% (w/v) 
117 dithiothreitol in equilibration buffer [50 mM Tris–HCl pH 8.8, 6 M 
118 Urea, 2% (w/v) sodium dodecyl sulfate (SDS) and 20% (v/v) glycerol] 
119 and then 2.5% (w/v) iodoacetamide in equilibration buffer for 15 min 
120 each. Strips were placed on top of 12–18% gradient SDS-PAGE resolving 
121 gels for the second dimension.A Fujifilm FLA-5100 scanner was used to 
122 scan each gel at the corresponding wavelengths to the CyDyes. Images 
123 were analyzed using SameSpots software (Progenesis) with a 1.2-fold 
124 change set as the cut off value and ANOVA (P b 0.05). 
125 2.3. Mass spectrometry analysis 
126 For identification of protein spots, gels were either silver (GE 
127 Healthcare) or Coomassie blue (Cheshire Sciences) stained using a 
128 mass spectrometry-compatible protocol. Spots were excised from 
129 the gel manually and washed three times with 50 μL of acetonitrile 
130 (ACN)/25 mM NH 4HCO 3 (2 :1) for 15 min each followed by 50 μL 
131 of 25 mM NH 4HCO 3 for 10 min. Gel pieces were then air dried for 
132 15 min and rehydrated in 5 μL of 12.5 ng/μL sequencing grade tryp-
133 sin (Promega) on ice for 20 min. 5 μl of 25 mM NH 4HCO 3 was added 
134 to each tube and incubated at 37 °C for 4 h. Tryptic digests were col-
135 lected, dried in a vacuum concentrator (Eppendorf) and 2 μl of 50% 
136 (v/v) ACN/0.1% (v/v) trifluoroacetic acid (TFA) was added to each 
137 tube. Finally, 0.5 μL of sample was transferred to the MALDI plate 
138 followed by 0.5 μL of 10 mg (w/v) α-cyano-4-hydroxycinnamic 
139 acid matrix (LaserBio Laboratories) in 50% (v/v) ACN/0.1% (v/v) 
TFA. Peptide mass fingerprints were generated using a MALDI-TOF 140 
mass spectrometer (Bruker Daltonics Ultraflex III MALDI-TOFTOF). 141 
Proteins were identified using the Mascot search engine (http://www. 142 
matrixscience.com); stating “Mus musculus” species, carbamidomethyl 143 
fixed and oxidized methionine as variable modifications and 100 ppm 144 
peptide tolerance. Positive identity was given by scores over 56 (com- 145 
paring Swiss-Prot database) and their molecular mass and pI were 146 
compared to the position of the spot on the 2D gel. 147 
2.4. Western blot analysis 148 
Mouse cortex was homogenized as described in 2D-DIGE. 50–100 μg 149 
was mixed with 2× reducing sample buffer [150 mM Tris–HCl pH 6.8, 150 
8 M Urea, 10% (v/v) SDS, 20% (v/v) glycerol, 10% (v/v) mercaptoethanol, 151 
3% (w/v) dithiothreitol, 0.1% (w/v) bromophenol blue]. Proteins were 152 
separated using 12% SDS-PAGE and transferred to nitrocellulose 153 
membrane. Blocking was for 1 h in 5% (w/v) Marvel in Tris-buffered 154 
saline containing 0.1% (v/v) Tween 20. Incubation in primary and 155 
corresponding horseradish peroxidase-conjugated secondary antibodies 156 
(Sigma) was overnight at 4 °C and for 1 h at room temperature respec- 157 
tively in blocking solution. The primary antibodies used were: 1:1000 158 
vimentin (GeneTex), peroxiredoxin 6 (GeneTex), glucose-regulated 159 
protein (Cell Signaling), protein disulphide isomerase (GeneTex), 160 
CCAAT-enhancer-binding protein homologous protein (Cell Signaling) 161 
and glial fibrillary acidic protein (Sigma); 1:500 fumerate hydratase 162 
(GeneTex); 1:250 stathmin (GeneTex); 1:200 X-box binding protein 163 
(Santa Cruz). Proteins were detected using enhanced chemiluminescence 164 
(Pierce). The band intensity was calculated with Quantity One 1-D anal- 165 
ysis Software and/or Aida. For 2D Western blot analysis, samples were 166 
separated as described in 2D-DIGE and following the second dimension 167 
processed to Western blotting as described here. 168 
2.5. Reactive oxygen species assay 169 
Levels of reactive oxygen species were examined using the 170 
2 ,7 -dichlorofluorescein diacetate — cellular reactive oxygen species 171 
detection assay kit (abcam) according to the manufacturer's instructions. 172 
Detection used fluorescent spectroscopy with excitation and emission of 173 
485 nm and 520 nm respectively. 174 
2.6. Lipid peroxidation 175 
Malondialdehyde (MDA) concentration was determined as an indi- 176 
cator of lipid peroxidation products based on the method of Erdelmeier 177 
et al. [13]. Mouse cortex was homogenized in 5 mMbutylated hydroxy- 178 
toluene in 20 mM phosphate buffer pH 7.4, followed by centrifugation 179 
at 3000 g for 10 min at 4 °C. Protein estimation used the Bio-Rad 180 
(Bradford) protein assay kit. 300 μl (9.5 μg/μl) was hydrolyzed 181 
using HCl pH 1–2 and incubated at 60 °C for 80 min. 60 μl of sample 182 
was mixed with 195 μl of 10.3 mM N-methyl-2-phenylindol in 3:1 183 
(v/v) acetonitrile:methanol and then 45 μl of concentrated HCl, 184 
incubated at 45 °C for 60 min and centrifuged at 15,000 g for 185 
10 min to clarify. Absorbance was measured spectrophotometrically 186 
at 586 n m . Concentration of malondialdehyde (μM/mg protein) was 187 
calculated using 1,1,3,3-tetramethoxypropane as a standard. 188 
2.7. Phospholipase A2 assay 189 
Phospholipase A2 (PLA2) activity (U/ml/mg protein) was determined 190 
using EnzChek Phospholipase A2 Assay kit (Invitrogen) according to the 191 
manufacturer's instructions. Detection used fluorescent spectroscopy 192 
with excitation and emission of 485 nm and 520 nm respectively. 193 
MJ33 inhibitor was used at 3 mol% based on previous reports [14,15]. 194 
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2.8. Protein oxidation 
Protein carbonyl content (nM/mg protein) was determined utilizing 
the 2,4-dinitrophenylhydrazine (DNPH) reaction following Cayman's 
Protein Carbonyl Colorimetric Assay Kit according to the manufacturer's 
instructions. Absorbance was measured spectrophotometrically at 
375 nm. 
2.9. Immunohistochemistry 
Mice were perfusion-fixed with 0.9% saline followed by 4% parafor-
maldehyde in phosphate buffered saline pH 7.4. The brains were then 
processed to paraffin with chloroform as the clearing agent. Immunohis-
tochemistry was performed as directed in Vector Laboratories M.O.M 
Immunodetection [GFAP (Sigma)] or Vectastain Elite Rabbit IgG [PRDX6 
(GeneTex) and MAP2 (abcam)] ABC kits using 0.01 M citrate buffer 
containing 0.05% Tween-20 pH 6 for antigen retrieval and appropriate 
fluorescently-conjugated secondary antibodies. 
2.10. Statistical analysis 
211 Results are expressed as mean average ± SEM. Statistical differ-
212 ences were analyzed by ANOVA and Student's t-test with significance 
213 set as indicated. 
Fig. 1. Representative 2D gel image of mouse brain cortex homogenate labeled with 
Cy5 dye and differentially-expressed protein spots between 26S proteasome-depleted 
and control mouse cortices highlighted (spots 1–24). Numbered spots showed 
1.2-fold change with statistical significance (ANOVA p b 0.05). Spots 1–16 were 
identified by peptide mass fingerprinting (Supplementary Table 1). 
214 3. Results 
215 3.1. 26S proteasomal depletion mouse model of neurodegeneration 
216 Generation of neurone-specific 26S proteasome-depleted mice has 
217 been described in detail previously [10]. To summarize, the Cre/loxP 
218 system spatially restricts inactivation of an essential subunit of the 19S 
219 regulatory particle of the 26S proteasome, ATPase Psmc1. PSMC1 is 
220 necessary for the assembly and activity of the 26S proteasome [10]. 
221 For forebrain neurone-specific inactivation of Psmc1, including cortex, 
222 floxed Psmc1 mice were crossed with mice expressing Cre recombinase 
223 under the control of the calcium calmodulin-dependent protein kinase 
224 IIα promoter (Psmc1 f l / f l; CaMKIIα-Cre). CaMKIIα is expressed in 
225 post-mitotic neurones from approximately post-natal week 2. We 
226 previously showed that 26S proteasomal depletion in mouse cortical 
227 brain neurones caused neurodegeneration and the formation of 
228 intraneuronal inclusion bodies accompanied by reactive gliosis at 
229 6 weeks of age [10]. The study here investigates proteomic changes 
230 accompanying neurodegeneration in the mouse cortex. 
231 3.2. Differentially-expressed proteins in 26S proteasome-depleted cortex 
232 Cortices from individual 6 week-old 26S proteasome-depleted and 
233 control (n = 4) mice were compared using 2D-DIGE proteomic analy-
234 sis and Progenesis SameSpots to identify differentially-expressed 
235 proteins. Fig. 1 shows a representative 2D gel image. The expression 
236 level of 24 spots showed statistically significant changes between 
237 26S proteasome-depleted and control animals ( 1.2-fold, ANOVA 
238 p b 0.05). Supplementary Table 1 lists the 19 proteins that were 
239 identified by peptide mass fingerprinting. The 2D-DIGE results and 
240 protein identifications were validated by Western blot analysis of 
241 selected differentially-expressed proteins based on antibody availabili-
242 ty. We confirmed by 1D Western blotting that expression of glial 
243 fibrillary acidic protein (GFAP; Fig. 1, spot 2), vimentin (VIME; Fig. 1, 
244 spot 1) and peroxiredoxin 6 (PRDX6; Fig. 1, spot 10) was significantly 
245 increased while mitochondrial fumarate hydratase (FUMH; Fig. 1, 
246 spot 4) and stathmin (STMN1; Fig. 1, spot 11) were significantly 
247 decreased in 26S proteasome-depleted vs. control cortex consistent 
248 with the 2D-DIGE analysis (Fig. 2). GFAP and VIME are associated 
249 with the intermediate filament system in astrocytes and their 
250 up-regulation is a hallmark of astrocyte activation and the resulting 
reactive gliosis [16]. This confirms our previously reported reactive 251 
astrogliosis by GFAP immunostaining of cortical brain sections following 252 
neuronal 26S proteasomal depletion [10]. PRDX6 has a well-known role 253 
as an antioxidant enzyme and its up-regulation in the cortex following 254 
26S proteasomal depletion is suggestive of oxidative stress [17–22]. 255 
FUMH is a key enzyme of the tricarboxylic acid (TCA) cycle and 256 
STMN1 has an important function in microtubule dynamics [23]. 257 
2D gel electrophoresis can separate isoforms of the same protein, 258 
whereas 1D Western blotting provides a single band of total protein. 259 
Fig. 3 shows differential expression of GFAP isoforms in 6 week-old 260 
mice using 2D Western blot analysis. Two predominant isoforms of 261 
GFAP were detected in the control and 26S proteasome-depleted 262 
mouse cortices (Fig. 3; spots 1 and 2). Four additional GFAP isoforms 263 
were detected in the 26S proteasome-depleted cortex (Fig. 3; spots 264 
3–6). Interestingly, GFAP was also identified in 2D-DIGE spot 9 265 
(Fig. 1 and Supplementary Table 1) that may correspond to spot 5 266 
or 6 in Fig. 3. We cannot exclude that the novel isoforms of GFAP 267 
detected in the 26S proteasome-depleted cortex may be present in 268 
the control cortex, but below the level of detection by this approach. 269 
GFAP isoforms may be associated with astrocyte subtypes that have 270 
specific functions and neuropathological conditions in the brain 271 
[24,25]. Alternatively, spots 5 and 6 may be GFAP protein breakdown 272 
products [26]. 273 
3.3. Neuronal 26S proteasomal depletion causes oxidative stress 274 
Since oxidative stress is a pivotal factor in neuronal death in neuro- 275 
degenerative diseases, we further investigated the antioxidant enzyme 276 
PRDX6 and oxidative stress in the mouse cortex following 26S 277 
proteasomal depletion. 278 
To investigate the levels of reactive oxygen species (ROS) in 279 
26S proteasome-depleted and control mouse cortices we used 280 
2 ,7 -dichlorofluorescein diacetate fluorogenic dye. This is the most 281 
widely used assay for measuring oxidative stress [27]. The levels of 282 
ROS were significantly increased in 26S proteasome-depleted corti- 283 
ces at 2 and half weeks of age (t-test p b 0.05; Fig. 4A). Because 284 
CaMKIIα is expressed in cortical neurones from approximately 285 
postnatal week 2, the data indicate that the ensuing loss of PSMC1 286 
and 26S proteasome activity causes oxidative stress. There was no 287 
significant difference in ROS levels between 26S proteasome-depleted 288 
and control mouse cortices at 3 weeks-old (Fig. 4B). At 4 and 6 weeks 289 
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Fig. 2. Validation and quantitation of identified protein changes following 26S proteasomal depletion in mouse cortex. 1D Western blot analysis of total cortical homogenates from 
6 week-old control and 26S proteasome-depleted (Psmc1fl/fl; CaMKIIα-Cre) mice for GFAP, VIME, PRDX6, FUMH and STMN1. A representative β-actin loading control is shown; this 
was performed for each Western blot. (B–F) Densitometry used QuantityOne software. Values were normalized to β-actin and represented as % vs. controls. Error bars represent 
SEM. n 3, *p b 0.05, **p b 0.01 (Student's t-test). 
290 of age there was a significant decrease in the levels of ROS in 26S 
291 proteasome-depleted cortices compared to controls (t-test p b 0.01; 
292 Fig. 4C and D). Linear regression analysis showed a significant correla-
293 tion between age and the levels of ROS in 26S proteasome-depleted 
294 cortex (p b 0.05; Fig. 4E). There was also a significant correlation 
295 between age and the levels of PRDX6 protein expression in 26S 
296 proteasome-depleted cortex between 2 and 6 weeks-old (p b 0.01; 
297 Fig. 4E). Importantly, there was an inverse relationship between the 
298 levels of PRDX6 protein expression and ROS in 26S proteasome-
depleted mouse cortex with increasing age, indicative of an antioxidant 299 
response of PRDX6 (Fig. 4E). 300 
3.4. Neuronal 26S proteasomal depletion causes increased lipid peroxidation 301 
High polyunsaturated fatty acid content makes the brain particu- 302 
larly susceptible to oxidative stress-associated lipid damage. Also, 303 
lipid peroxidation is known to be an autocatalytic process, amplifying 304 
the destructive effects of the initial free radical [28,29]. Quantitation 305 
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Fig. 3. Protein isoform expression of GFAP revealed by 2D Western blotting of control and 26S proteasome-depleted (Psmc1fl/fl; CaMKIIα-Cre) mouse cortices. Arrows indicate six 
GFAP isoforms. 
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Fig. 4. Increased PRDX6 protein expression is associated with decreased reactive oxygen 
species (ROS). Levels of ROS (A–D) in control and 26S proteasome-depleted (Psmc1fl/fl; 
CaMKIIα-Cre) cortices. Data represented as mean ± SEM. n 6, *p b 0.05, **p b 0.01 
(Student's t-test). (E) Inverse relationship between the levelsofPRDX6 protein expression 
and ROSin26S proteasome-depleted mouse cortex with increasing age. Data represented 
as mean ± SEM. 
306 of malondialdehyde (MDA), a toxic secondary product of membrane 
307 lipid peroxidation, in cortical tissue homogenates between 4 and 
308 6 weeks of age identified significantly increased levels of MDA in 5 
309 and 6 week-old 26S proteasome-depleted mice compared to controls 
310 (t-test p b 0.01; Fig. 5A–C), indicating that lipid oxidation is increased 
311 following neuronal 26S proteasomal depletion. 
312 Protein carbonyls are hallmarks of the oxidative status of pro-
313 teins. Therefore, to further investigate oxidative stress, we evaluated 
314 carbonyl content spectrophotometrically using a reaction with 
315 2,4-dinitrophenylhydrazine in mouse cortical tissue homogenates. 
No significant difference in the levels of protein carbonyls was ob- 316 
served between 26S proteasome-depleted and control mouse corti- 317 
ces at 6 weeks-old (Supplementary Fig. 1) . 318 
3.5. Increased phospholipase A2 activity in 26S proteasome-depleted 319 
cortex 320 
Interestingly, PRDX6 is a bifunctional enzyme with peroxidase and 321 
phospholipase A2 (PLA2) activities [30]. The PLA2 activity of PRDX6 322 
has not been studiedaswidely as the peroxidase-associated antioxidant 323 
properties. Quantitation of PLA2 activity in 26S proteasome-depleted and 324 
control cortical homogenates between 4 and 6 weeks of age showed sig- 325 
nificantly increased activity in the 6 week-old 26S proteasome-depleted 326 
mouse cortex (t-test p b 0.01; Fig. 5D–F). The chemical inhibitor MJ33 327 
that has previously been shown to have some (although not total) 328 
specificity for PRDX6 PLA2 activity [14,15] significantly decreased PLA2 329 
activity in 26S proteasome-depleted cortex, suggesting that some of the 330 
PLA2 activity was associated with PRDX6 (Fig. 5F). 331 
3.6. Astrocytic localization of PRDX6 332 
To investigate the cellular localization of PRDX6 we performed 333 
double immunofluorescent labeling of brain sections with PRDX6 and 334 
GFAP or 200 kD neurofilament heavy chain (NF-H) for astrocytes and 335 
neurones respectively (Fig. 6 and Supplementary Fig. 2). PRDX6 336 
immunolabeled cells with the characteristic morphology of astrocytes 337 
in control and 26S proteasome-depleted cortices from 6 week-old 338 
mice (Fig. 6). Double-labeling with GFAP confirmed the localization of 339 
PRDX6 in astrocytes in the 26S proteasome-depleted mice (Fig. 6; 340 
right-hand panel). GFAP is the most widely used marker for immunohis- 341 
tochemical identification of astrocytes and labels reactive astrocytes that 342 
are responding to central nervous system (CNS) damage, but it is 343 
recognized that not all non-reactive astrocytes in the healthy CNS 344 
are identified by GFAP [31]. Therefore, PRDX6 expression in the 345 
control mouse brain is in non-reactive astrocytes that are not 346 
immunohistochemically labeled by GFAP (Fig. 6; left-hand panel). 347 
Importantly, we noted a much higher diffuse PRDX6 staining in the 348 
26S proteasome-depleted cortical brain sections compared to the 349 
control (Fig. 6; compare i and ii), suggesting PRDX6 may be secreted 350 
by activated astrocytes in response to the neuronal changes. The 351 
expression of PRDX6 did not co-localize with NF-H in mouse cortical 352 
neurones (Supplementary Fig. 2) . 
4. Discussion 
Proteomic studies of human post-mortem brain and disease models 
are of considerable interest to understand pathogenic mechanisms 
connected to neurodegenerative disease. This study has identified and 
validated several differentially-expressed proteins accompanying 
neurodegeneration in the mouse cortex following neuronal 26S 
proteasomal depletion. Among these, the antioxidant enzyme PRDX6 
was significantly increased. Since oxidative stress is a pivotal factor in 
human neurodegenerative diseases [32,33], supported by animal and 
cellular models [33–35], we further investigated PRDX6 and oxidative 
stress in the 26S proteasome-depleted mouse cortex. 
Here we have shown a significant inverse relationship between the 
levels of PRDX6 protein expression and ROS following 26S proteasomal 
depletion in the mouse cortical neurones, indicative of oxidative stress 
and an antioxidant response of PRDX6. Lipid peroxidation was also 
significantly increased in the cortex of 26S proteasome-depleted mice. 
Similar to the other PRDXs and glutathione peroxidase family, PRDX6 
can reduce hydrogen peroxide and short chain hydroperoxides, but 
PRDX6 can also directly bind and reduce phospholipid hydroperoxides 
[36,37]. This characteristic plays an important role in its antioxidant 
defense [19,20]. Studies in cell and mouse models demonstrate that 
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Fig. 5. Neuronal 26S proteasomal depletion causes increased lipid peroxidation and PRDX6 PLA2 activity. Quantitation of MDA (A–C) and PLA2 activity (D–F) in control and 26S 
proteasome-depleted (Psmc1fl/fl; CaMKIIα-Cre) cortices at 4, 5 and 6 weeks of age. (F) PLA2 activity is significantly decreased by chemical inhibitor MJ33 at 6 weeks of age. Data 
presented as mean ± SEM. n 4, **p b 0.01 (Student's t-test). 
375 decreased expression or overexpression of PRDX6 results in increased 
376 sensitivity or resistance to oxidant stress respectively [17–22]. 
377 PRDX6 is a bifunctional enzyme with peroxidase and PLA2 activities 
378 [30]. Increased PLA2 activity in 26S proteasome-depleted cortex corre-
379 lates with increased PRDX6 expression. Given previous studies have 
380 shown that the PLA2 activity of PRDX6 is sensitive to MJ33 [14,15], we 
381 propose that the decreased PLA2 activity in the presence of MJ33 is 
382 partly attributable to PRDX6. However, we recognize that MJ33 is not 
383 totally specific for PRDX6 and that other phospholipases that have 
384 not been investigated in this study presumably explain the MJ33-
385 insensitive PLA2 activity [38]. 
386 The PLA2 activity of PRDX6 has been associated with several cellular 
387 functions. PLA2 enzyme activity liberates both a free fatty acid and 
388 lysophosphatidylcholine from phosphatidylcholine substrates and has 
389 been implicated in oxidative stress-induced apoptosis and inflamma-
390 tion [39–42]. Importantly, a recent study in pulmonary microvascular 
391 endothelial cells suggested that the PLA2 activity of PRDX6 may also 
392 play a role in antioxidant protection provided by PRDX6 [43]. 
393 The cellular distribution of PRDX6 in our mouse model is similar to 
394 previous studies in mouse and human brain showing expression of 
395 PRDX6 mainly in astrocytes [44–49]. A study in mouse brain neural 
396 cell types showed differential expression patterns of the six mammalian 
397 isoforms of the PRDX family and only PRDX6 was found in astrocytes, 
398 which may be indicative of a specific role in their function [46]. Impor-
399 tantly, an increase in PRDX6 and the number and staining intensity of 
400 PRDX6-positive astrocytes has been described in human brain regions 
401 affected in AD, PD and DLB, as well as other neurodegenerative disease 
402 mouse models [44,45,47,49,50]. Since oxidative stress is regarded as a 
403 fundamental process in the events that lead to neurodegeneration, the 
404 antioxidant function of PRDX6 may play an important neuroprotective 
405 response of the astrocyte [32,51,52]. Further support for PRDX6 in this 
context was shown in parkin-deficient mice, where PRDX6 was 406 
downregulated [53]. 407 
We also noted a much higher diffuse PRDX6 staining in the 26S 408 
proteasome-depleted cortical brain sections compared to the control, 409 
suggesting PRDX6 may be secreted by activated astrocytes. This is 410 
supported by previous studies that have suggested that this enzyme 411 
may be a secreted protein [44,54]. Evidence suggests PRDX6 is 412 
present at very low levels in neurones and an early study in PD and 413 
DLB disease brains demonstrated the presence of PRDX6 in Lewy 414 
bodies [44,46–49]. However, PRDX6 expression was not detectable 415 
in neurones or inclusion bodies in our mouse model. 416 
This is the first in vivo report of oxidative stress caused directly by 417 
neuronal 26S proteasome dysfunction in the mammalian brain. Our 418 
findings are supported by cellular studies using chemical proteasome 419 
inhibitors [55–57]. Various antioxidant defenses have also been dem- 420 
onstrated in response to proteasome inhibitor oxidative stress [57], 421 
but PRDX6 has not been described previously and most likely because 422 
studies were not focused on the brain. Since the high polyunsaturated 423 
fatty acid content makes the brain particularly susceptible to lipid 424 
peroxidation, the unique ability of PRDX6 to reduce phospholipid 425 
hydroperoxides may play an important role in antioxidant protection 426 
in the brain. 427 
Increased astrocytic PRDX6 expression was associated with de- 428 
creased levels of ROS, and together with the presence of oxidative 429 
stress, supports an antioxidant neuroprotective role of astrogliosis 430 
in response to neurodegeneration caused by 26S proteasome deple- 431 
tion in mouse brain neurones. However, the astrocytic network has 432 
a wide range of activities that can be both beneficial and detrimental 433 
such as energy metabolism and the release of inflammatory mole- 434 
cules respectively [31,58]. We emphasize that the PLA2 activity of 435 
PRDX6 may also be involved in the production of further mediators 436 
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Fig. 6. Astrocytic localization of PRDX6 in the mouse cortex. Double immunofluorescent 
labeling of cortical brain sections from control and 26S proteasome-depleted (Psmc1fl/fl; 
CaMKIIα-Cre) 6 week-old mice with GFAP (green) and PRDX6 (red). DAPI (blue) was 
used as a fluorescent nuclear counterstain. Enlarged views of the boxed areas are shown 
(zoom). Note much higher diffuse PRDX6 staining in the 26S proteasome-depleted 
cortical brain sections in addition to the more focused staining in astrocytes (compare i 
and ii). Scale bar, 50 μm. 
437 related to cellular signaling functions that may be protective or dele-
438 terious in the progressive neuronal loss. 
439 The intercellular signaling molecule(s) and mechanism(s) that 
440 modulate reactive astrogliosis in response to neurodegeneration fol-
441 lowing 26S proteasomal depletion in neurones will require further 
442 study. Diverse molecules have been suggested that can be released 
443 by all central nervous system cell-types, including ROS [58,59]. In-
444 terestingly, we report here that mitochondrial FUMH, a key enzyme 
445 of the TCA cycle, is decreased in the 26S proteasome-depleted cortex 
and may reflect mitochondrial dysfunction. We recently reported 446 
that 26S proteasomal depletion in mouse brain neurones leads to the 447 
formation of inclusions composed predominantly of morphologically 448 
abnormal mitochondria with disrupted or disintegrated cristae [60]. A 449 
spectrum of mitochondrial pathologies that may be associated with 450 
oxidative stress has been described in human neurodegenerative 451 
diseases and associated disease models, including perturbed respiratory 452 
chain function, mitochondrial dynamics and clearance [32,33,61]. 453 
Therefore, we suggest that mitochondrial dysfunction may be impor- 454 
tant in the mechanism of oxidative stress and neurodegeneration 455 
following 26S proteasome depletion. 456 
Proteasome inhibition is known to induce endoplasmic reticulum 457 
(ER) stress and activation of the unfolded protein response (UPR) 458 
signaling pathways [62–64]. ER stress is associated with the production 459 
of ROS from the ER as well as mitochondria and evidence of ER stress 460 
has been shown in various human neurodegenerative diseases, such 461 
as AD and PD [65–68]. Investigation of key mammalian ER 462 
stress-induced proteins; the chaperone glucose-regulated protein 78 463 
(GRP78), the transcription factor X-box binding protein-1 (XBP1), 464 
protein disulphide isomerase (PDI) and the cell death mediator 465 
CCAAT-enhancer-bindingprotein homologous protein (CHOP), showed 466 
that neuronal 26S proteasomal depletion does not cause activation of 467 
the UPR (Supplementary Fig. 3) [69,70]. Taken together, ER stress is 468 
not an important source of ROS in this model. 469 
Although we found evidence for increased oxidation of lipids 470 
indicative of oxidative stress in the cortex following neuronal 471 
26S proteasome depletion, protein oxidation was not increased. 472 
Proteasome function is known to be important for t h e degradation 473 
of oxidatively modified proteins [71–75]. Therefore, we may have 474 
expected to find increased protein oxidation following 26S 475 
proteasome depletion in the mouse cortex due to increased oxida- 476 
tive stress and/or decreased removal of oxidatively modified 477 
proteins. However, in the heterogeneous population of cellular 478 
proteasome complexes, the 26S proteasome has a relatively minor 479 
role in the removal of oxidatively damaged proteins compared to 480 
the 20S proteasome [72,73,76–78]. We previously showed that 481 
inactivation of Psmc1 specifically disrupts 26S proteasome function; 482 
assembly and activity of the 20S core proteolytic proteasome was 483 
not affected [10]. Therefore, 20S proteasome function in Psmc1; 484 
CaMKIIα-Cre neurones may be sufficient to protect cells from protein 485 
oxidative modification. Alternatively, it is possible that the level of 486 
protein oxidation was not sufficient for detection in a mixed cell 487 
population of targeted (CaMKIIα) and non-targeted neurones and 488 
glia. 489 
Different quantitative proteomic approaches will favor different 490 
subpopulations of proteins. 2D-DIGE fluorescence-based detection 491 
provides high sensitivity that is linear over several orders of magni- 492 
tude [79,80]. The significant advantage of this technology is the ability 493 
to multiplex using different fluorescent cyanine dyes, providing 494 
greater accuracy of quantitation over conventional 2D gel approaches 495 
[79]. However, the percentage of lysine residues in proteins may 496 
affect labeling efficiency and current in-gel digestion and mass spec- 497 
trometers limit identification of lesser abundant proteins detected 498 
by 2D-DIGE [79]. Together with the well-known limitations of 2D 499 
gel electrophoresis, i.e. hydrophobic proteins, dynamic range and 500 
quantitative distribution issues, our study may miss some important 501 
molecular players involved in the orchestration of cellular events 502 
following neuronal 26S proteasomal depletion [79–81]. 503 
In conclusion, we reveal that oxidative stress may contribute 504 
to the cellular events leading to neurodegeneration following UPS 505 
dysfunction, providing a novel intersection between two prominent 506 
hypotheses in disease pathogenesis. Increased astrocytic expression 507 
of PRDX6 also reveals innovative information regarding the role of 508 
neuronal–glial interactions and astrogliosis in neurodegeneration. 509 
Supplementary data to this article can be found online at http:// 510 
dx.doi.org/10.1016/j.bbadis.2013.07.002. 511 
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